Picard Medical (NYSE: PMI) details new investor presentation filing

Rhea-AI Filing Summary

Picard Medical, Inc. filed a current report to make public an investor presentation it plans to use for investor relations and other purposes. The presentation is included as Exhibit 99.1, dated January 13, 2026, and is incorporated by reference in the report.

The company specifies that the information in this report and the attached exhibit is being "furnished" rather than "filed," meaning it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other Securities Act or Exchange Act filings.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0002030617 0002030617 2026-01-13 2026-01-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 13, 2026

Picard Medical, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-42801		86-3212894
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1992 E Silverlake
Tucson AZ, 85713

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (520) 545-1234

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		PMI		The NYSE American, LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On January 13, 2026, Picard Medical, Inc. (the “Company”) published an investor presentation (the “Presentation”) that it plans to use for investor relations and other purposes. A copy of the Presentation is attached as Exhibit 99.1 and is incorporated herein by reference.

The information in this report and the exhibit attached hereto shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are being filed herewith:

Exhibit No.		Description
99.1		Investor Presentation (January 13, 2026)
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Picard Medical, Inc.
	By:	/s/ Patrick NJ Schnegelsberg
		Name:	Patrick NJ Schnegelsberg
		Title:	Chief Executive Officer

Dated: January 13, 2026

2

FAQ

What did Picard Medical (PMI) disclose in this 8-K?

Picard Medical disclosed that it published an investor presentation to be used for investor relations and other purposes, and attached it as Exhibit 99.1 dated January 13, 2026.

Where can investors find the new Picard Medical (PMI) investor presentation?

The investor presentation is included as Exhibit 99.1 to the report and is incorporated by reference, providing access to the full set of materials.

Is the Picard Medical (PMI) investor presentation considered "filed" with the SEC?

No. The company states that the report and Exhibit 99.1 are "furnished" and not deemed "filed" for purposes of the Exchange Act, limiting related liabilities and incorporation by reference.

Does this Picard Medical (PMI) filing include financial results or guidance?

The report only states that an investor presentation was published and attached as an exhibit; it does not describe specific financial results or guidance within the body of the report.

What is the stated purpose of Picard Medical’s new investor presentation?

The presentation is intended for investor relations and other purposes, suggesting it is designed to communicate the company’s story and key information to investors and stakeholders.